New daily pill could cut migraine days in half

NCT ID NCT06414044

Ongoing Disease control Sponsor: University of Florence Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is tracking 500 Italian adults with migraine to see how well the daily pill atogepant works in everyday life. Researchers will measure changes in monthly migraine days over a year. The goal is to find out if atogepant is a safe and effective preventive treatment for people with episodic or chronic migraine.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atogepant
What this could lead to: If successful, this could show that atogepant is a safe and effective daily pill to prevent migraines in real-world patients.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It is also limited to Italian patients, so findings may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Headache Headache Disorders, Secondary migraine disorder migraine with aura migraine without aura Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MIGRAINE MIGRAINE MIGRAINE WITH AURA MIGRAINE WITHOUT AURA

Contacts and locations

Locations

Fondazione Policlinico Campus Bio-Medico

Roma, 00128, Italy
SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi

Florence, 50134, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.